

Supplementary File 1: Data extracted from publications of confirmatory

Drug (generic name)	Company	Indication	Publications	Outcome used in study		Number of patients			Age of patients	Sex distribution	Randomiz ed	Blinded	Observatio nal
				Surrogate	Clinical	Treatment	Control (active)	Control (placebo)					
Abacavir	GlaxoSmithK line	HIV/AIDS	Staszewski et al. JAMA 2001;285:1155- 1163	1		246	241	median: 36 (treatment), = 75 36 (control)	M = 487, F = 75	1	1	0	
			Katlama et al. HIV Medicine (2001) 2, 27-34	1		92	93	no mean/medi an age given	not stated	1	1	0	
			Rozenbaum et al. Antiviral Therapy 2001;6:135-142	1		35	40	median: 33 (treatment), 27 33 (control)	M = 48, F = 27	1	0	0	
Alteplase	Hoffman- LaRoche	stroke	Hill et al. CMAJ 2005;172(10):1307- 12		1	1135		no mean/medi an age given	M = 623, F = 512	0	0	1	
			Hacke et al. Can J Neurol Sci 2001;28:232-8		1	409	391	median: 68	M = 469, F = 331	1	1	0	
Anastrozole	AstraZeneca	breast cancer	ATAC Trialist Group. Lancet 2005;365: 60-62	1		3092	3094	no mean/medi an age given	M = 0, F = 6186	1	1	0	
Bortezomib	Janssen	replaced multiple myeloma	Richardson et al. N Engl J Med 2005;352:2487-98		1	333	336	median: 62 (treatment), = 281 61 (control)	M = 388, F = 281	1	0	0	
		progressive multiple myeloma	Richardson et al. N Engl J Med 2005;352:2487-98*		1	333	336	median: 62 (treatment), = 281 61 (control)	M = 388, F = 281	1	0	0	
Capecitabin e	Hoffman- LaRoche	bowel cancer	Twelves et al. Annals of Oncology 2012;23:1190-119 7		1	1004	983	no mean/medi an age given	M = 1074, F = 912	1	0	0	
Crizotinib	Pfizer	lung cancer	Solomon et al. NEJM 2014;371:2167- 2177	1		172	171	median: 52 (treatment), = 212 54 (control)	M = 131, F = 212	1	0	0	
			Shaw et al. NEJM 2013;368:2385- 2394	1		173	174	median: 51 (treatment), = 194 49 (control)	M = 153, F = 194	1	0	0	
Darunavir	Janssen	HIV/AIDS	Arasteh et al. Antiviral Therapy 2009;14:859-864	1		467	124	no mean/medi an age given	not stated	1	1	0	

			Madruza et al. Lancet 2007; 370: 49-58	1	286	291	mean: 40.9 M = 470, F = 125	1	0	0
Dasatinib	Bristol-Myers Squibb	chronic, accelerated, or blast phase chronic myeloid leukemia	Guilhot et al. Blood 2007 109: 4143-4150	1	107		median: 57 M = 55, F = 52	0	0	1
			Saglio et al. N Engl J Med 2010;362:2251-9	1	563	283	median: 47 M = 491, F (treatment), = 355 46 (control)	1	0	0
		chronic myeloid leukemia (CML) in chronic phase	Kantarjian H et al. N Engl J Med. 2010;362:2260-70	1	259	260	median: 46 M = 307; F (treatment), = 212 49 (control)	1	0	0
			Radich JP et al. Blood 2012;120:3898-905	1	123	123	median: 47 M = 146, F (treatment) = 100 , 50 (control)	1 not stated		0
Eculizumab	Alexion	paroxysmal nocturnal haemoglobinuria	Greenbaum et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International 2016;89:701-711	1	22		median: 6.5 M = 12, F = 10	0	0	1
			Fakhouri et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm open-	1	41		mean: 40 M = 13, F = 28	0	0	1
Exemestane	Pfizer	breast cancer	Coombes et al. Lancet 2007;369:559-70	1	2352	2372	no mean/median age given M = 0, F = 4724	1 not stated		0
			Bliss et al. Journal of Clinical Oncology 2012;30:709-717	1	2319	2338	mean: 64.2 M = 0, F = 4657	1 not stated		0

			Fallowfield et al. Br J Cancer 2012;106:1062-7	1	289	293	no mean/median age given	M = 0, F = 582	1 not stated	0
Gefitinib	AstraZeneca	lung cancer	Thatcher et al. Lancet 2005;366:1527-37	1	1129	563	median: 62 (treatment), 61 (control)	M = 1139, F = 553	1 1	0
			Kim et al. Lancet 2008;372:1809-1818	1	733	733	not stated if median or mean: 61 (treatment), 60 (control)	M = 954, F = 512	1 0	0
			Natale et al. Journal of Clinical Oncology	1	85	83	median: 61 (treatment), 63 (control)	M = 100, F = 68	1 1	0
Lenalidomide	Celgene	myelodysplastic syndromes	Fenaux et al. Blood 2011 118: 3765-3776	1	138	67	median: 66 (treatment, 5 mg), 68 (treatment, 10 mg), 70 (control)	M = 32, F = 106	1 1	0
Levodopa/carbidopa	AbbVie	Parkinson's disease	Olanow et al. Lancet Neurol 2014; 13: 141-149	1	35	31	not stated if median or mean: 63.7 (treatment), 65.1 (control)	M = 46, F = 25	1 1	0
			Slevin et al. Journal of Parkinson's Disease 2015;5:165-74	1	62	62	mean: 64.1 (treatment), 65.1 (control)	M = 44, F = 18	0 0	1
Pregabalin	Pfizer	central neuropathic pain	Kim et al. Pain 2011;152:1018-1023	1	110	109	mean: 57.1 (treatment), 59.4 (control)	M = 137, F = 73	1 1	0
Recombinant factor VIIa	Novo Nordisk	clotting disorders	Pruthi et al. Thromb Haemost 2007;98:726-732	1	12	12	median: 37.4 (treatment), 26.7 (control-active), 31 (control - placebo)	M = 36, F = 0	1 0	0
Simeprevir	Janssen	hepatitis C	Kwo et al. Hepatology 2016;64:370-80	1	310	310	not stated if mean or median: 58	M = 169, F = 141	1 0	0
			Lawitz et al. Hepatology 2016;64:360-369	1	103	103	not stated if mean or median: 58,	M = 83, F = 20	0 0	1

Sorafenib	Bayer	kidney cancer	Escudier et al. Journal of Clinical Oncology 2009;27:3312-3318	1	451		452 median: 59 M = 677- (treatment), 686, F = 59 (control); 226-217 mean: 58.5 (percent (treatment), male 75-76) 58.3 (control)	1	1	0
			Pena et al. Clinical Cancer Research 2010;16:4853-4863	1	451		452 no mean/medi an age given M = 650- 668, F = 253-235 (percent male 72-74)	1 not stated		0
Sunitinib	Pfizer	second line treatment of kidney cancer	Motzer et al. Journal of Clinical Oncology 2009;27:3584-3590	1	375	375	no mean/medi an age given not stated	1	0	0
			Motzer et al. N Engl J Med 2007;356:115-24	1	375	375	median: 62 M = 536, F (treatment), = 214 59 (control)	1	0	0
		first-line treatment of kidney cancer	Motzer et al. JAMA 2006;295:2516- 2524	1	106		median: 56 M = 67, F = 39	0	0	1
Zanamivir	GlaxoSmithK line	influenza	Motzer et al. Journal of Clinical Oncology	1	375	375	no mean/medi an age given not stated	1	0	0
			Hedrick et al. Pediatric Infectious Diseases Journal	1	224		247 mean: 8.8, M = 258, F median: 9 = 213	1	1	0

\*duplicate study